STAT3 and lung cancer: Moreover, our study highlights the clinical relevance of these findings, demonstrating the increased expression of SHH, p‐STAT3, and GLI1 proteins in postosimertinib‐resistant lung cancer tissues, along with decreased DUSP13B expression.